ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

How Compounded Treatments Are Helping Hims & Hers Customers Meet Their Weight Loss Goals

Hims & Hers today released a white paper on how its customers are thriving and seeing meaningful results through personalized weight loss solutions

Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today released a white paper entitled “Hims & Hers Weight Loss: A Look at Early Customer Experiences and Outcomes” which outlines how customers are achieving positive outcomes with compounded medications through our weight loss program. Early customer results indicate they are managing side effects well, staying on treatment, and overall feeling healthier.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241029420293/en/

Data from Hims & Hers Weight Loss: A Look at Early Customer Experiences and Outcomes outlines how customers are achieving positive outcomes within our weight loss program. Early customer results indicate they are managing side effects well, staying on treatment, and overall feeling healthier. (Photo: Business Wire)

Data from Hims & Hers Weight Loss: A Look at Early Customer Experiences and Outcomes outlines how customers are achieving positive outcomes within our weight loss program. Early customer results indicate they are managing side effects well, staying on treatment, and overall feeling healthier. (Photo: Business Wire)

The United States is in the midst of an obesity epidemic. 70% of American adults have obesity or are overweight. According to the World Health Organization (WHO), at least 2.8 million people die each year due to being overweight or obese. To help solve the obesity crisis in America, successful weight loss solutions are critical to helping patients prosper. We need weight loss solutions that can meet intense ongoing consumer demand, are cost-effective, and are tailored to individuals’ unique needs and sensitivities.

“We are laser focused on increasing access to world-class personalized care in the highest impact areas of health and wellness,” said Dr. Patrick Carroll, Chief Medical Officer of Hims & Hers. “With over 40% of our nation’s adults considered obese our country demands that we use our expertise, size, and industry leadership to answer the very real obesity crisis in the United States and be a part of the solution for the millions of Americans who have obesity and are looking for help.”

According to data highlighted in the company’s latest white paper, research shows that Hims & Hers weight loss solutions are helping customers achieve positive health outcomes. Key findings include:

  • Customers using oral medication kits on average, lost 7.5 pounds - approximately 3.6% of their initial body weight - in their first month.
  • Customers using compounded GLP-1s lost an average of 9.3 pounds - approximately 4.1% of their initial body weight - in their first month.
  • 79% of compounded GLP-1 customers reported that their treatment experience had met or exceeded their expectations.
  • 90% of compounded GLP-1 customers are satisfied with their personalized dosing plan and 87% reported they are progressing towards their weight loss goal, very close to meeting their weight loss goal, or had already achieved their weight loss goal.

The research also suggests that Hims & Hers’ weight loss offering is sustainable, allowing its customers to stay on their treatments and achieve lasting results.

  • Only 13% of compounded GLP-1 customers cancel their treatment subscription in the first month. This is significant when compared to a recent Blue Cross Blue Shield finding that over 30% of commercially insured adults prescribed GLP-1 treatment discontinue within the first four weeks, which may be because of discomfort with early side effects, the high cost of certain weight loss treatments, and limited access to care.
  • 80% of compounded GLP-1 customers who report side effects like nausea say the side effects are tolerable, indicating they plan to continue their treatment, despite mild side effects.

Since December 2023, Hims & Hers has provided its customers access to weight loss solutions. The Hims & Hers program offers a holistic, cost-effective, and personalized approach to reducing weight that includes:

  • Medication management: Following consultation with a licensed healthcare provider on the platform, patients may be prescribed medication that is personalized based upon individual patients’ weight loss goals, medical history, needs, and preferences.
  • Nutrition, exercise, and mental health support: Through the Hims & Hers app, patients have access to educational and motivational content that offers nutrition guidance, recipes, exercise recommendations, sleep advice, and mental health support. All content is personalized based on the individual’s lifestyle and appetite profile.
  • Digital tracking tools: Through the Hims & Hers app, patients can track their progress, hydration, movement, and sleep.
  • 24/7 access to a care team: Individuals can message their care team at any time through the Hims & Hers app.

“The data and insights we have been able to glean through our research show that our customers are having meaningful health outcomes when it comes to weight loss,” said Dr. Jessica Yu, Senior Director of Patient Experience at Hims & Hers. “The data shows our customers are experiencing good weight loss on compounded medications, having manageable side-effects through personalized dosing, suggesting the treatment is sustainable and they are making positive strides towards a healthier future. The importance of these findings is significant as we believe early customer satisfaction and adherence to treatment is likely to enhance long-term outcomes and even more important as we continue to search for ways to manage the obesity crisis in our nation.”

Download the full white paper here.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.